Enter to open, tab to navigate, enter to select
Hatch-Waxman Patent Litigation Toolkit
Practical Law Toolkit 8-614-9393 (Approx. 9 pages)
Hatch-Waxman Patent Litigation Toolkit
by Practical Law Intellectual Property & Technology
| Maintained • USA (National/Federal) |
Resources for counsel involved in litigation arising under the Hatch-Waxman Act based on a generic drug manufacturer's filing of an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration (FDA), including background information on the Hatch-Waxman Act, pre-suit considerations for a patent owner's counsel, litigation documents and settlement issues. It also covers Biosimilars Litigation under the Biologics Price Competition and Innovation Act (BPCIA).
Patent litigation arising under the Hatch-Waxman Act based on the filing of an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration (FDA) presents unique challenges for litigants and their counsel. Parties and their counsel should be aware of the differences between general patent litigation and Hatch-Waxman patent litigation, both before litigation starts and once a patent infringement complaint is filed.
This Toolkit provides several continuously maintained resources designed to help both patent owners' and ANDA filers' counsel prepare for and conduct patent litigation arising under the Hatch-Waxman Act, including resources relating to:
- The Hatch-Waxman Act generally.
- A patent owner's pre-suit preparations before and after an ANDA filing.
- Infringement claims under 35 U.S.C. § 271(e)(2).
- Preparing a patent infringement complaint.
- Discovery.
- Settlement and related antitrust considerations.
The Toolkit also includes several resources discussing litigation under the Biologics Price Competition and Innovation Act (BPCIA) (see Biosimilars Litigation Under the BPCIA).